Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EKLV | ISIN: US35168W1036 | Ticker-Symbol:
NASDAQ
27.06.25 | 21:53
1,675 US-Dollar
-3,74 % -0,065
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
FRACTYL HEALTH INC Chart 1 Jahr
5-Tage-Chart
FRACTYL HEALTH INC 5-Tage-Chart

Aktuelle News zur FRACTYL HEALTH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FRACTYL HEALTH Aktie jetzt für 0€ handeln
DiFractyl Health-Aktie behält Kaufempfehlung bei Canaccord nach positiven Studiendaten4
DiFractyl Health stock maintains Buy rating at Canaccord on positive trial data1
MoFractyl Health-Aktie stabil, während Evercore ISI Outperform-Rating bestätigt2
MoFractyl Health stock steady as Evercore ISI reiterates outperform rating1
MoFractyl Health Reports 3-Month REVEAL-1 Data Suggesting Durable Weight Maintenance, Stock Down-
MoFractyl berichtet über positive 3-Monats-Daten zur Gewichtserhaltung nach GLP-1-Therapie1
MoFractyl reports positive 3-month data for post-GLP-1 weight maintenance1
MoFractyl Health, Inc.: Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy10712 of 13 participants maintained or lost weight at 3 months, with 6 of 13 losing additional weight after stopping GLP-1 therapy and undergoing Revita procedure Median weight remained stable through...
► Artikel lesen
MoFractyl Health, Inc.: Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical ...1
18.06.Fractyl Health receives two new patents for duodenal resurfacing tech2
18.06.FRACTYL HEALTH, INC. - 8-K, Current Report1
13.06.Fractyl Health, Inc.: Fractyl Health to Present New Preclinical Data from its Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions3
04.06.Fractyl Health, Inc.: Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita Across its Bariatric and Metabolic Endoscopy Centers Nationwide1
19.05.Fractyl Health advances gene therapy for diabetes treatment1
19.05.Fractyl Health treibt Gentherapie für Diabetesbehandlung voran2
19.05.Fractyl Health, Inc.: Fractyl Health Advances Rejuva Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes174First-in-human study will evaluate safety, tolerability, and early efficacy of a one-time, pancreas-targeted smart GLP-1TM gene therapy for patients with inadequately controlled T2D and obesity Expect...
► Artikel lesen
19.05.FRACTYL HEALTH, INC. - 8-K, Current Report2
17.05.Fractyl Health, Inc.: Fractyl Health Unveils New Rejuva Smart GLP-1 Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025105Data suggests that single dose of RJVA-001 leads to durable metabolic improvements with low systemic GLP-1 exposure in db/db mouse model of T2D- potentially simultaneously addressing durability, adherence...
► Artikel lesen
14.05.Fractyl Health Partners with Forge for Rejuva Gene Therapy Development1
14.05.Fractyl signals accelerated enrollment for REMAIN-1 study while advancing Rejuva clinical milestones1
Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1